The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata

Learn more about:
Related Clinical Trial
A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata Modified SALT Score for Alopecia Areata Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss – Alopecia Areata TREg Activation in the Treatment of the PELADE (Alopecia Areata) The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata Response of Topical Capsaicin in Alopecia Areata Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. Jaktinib Dihydrochloride Monohydrate in Severe Alopecia Areata Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade Stem Cell Educator Therapy in Alopecia Areata Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Vytorin in the Treatment of Alopecia Areata Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Efficacy and Safety of LH-8 in Paediatric Alopecia Areata Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Intralesional Steroids in the Treatment of Alopecia Areata A Phase II Study in Patients With Alopecia Areata Topical Crisaborole in Patients With Alopecia Areata Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females Excimer Light for Alopecia Areata Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata Safety and Efficacy Study of SHAPE Gel in Alopecia Areata Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata Topical Garlic Concentrate for Alopecia Areata in Children Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Aldara for the Treatment of Extensive Alopecia Areata A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata LEO 124249 Ointment in the Treatment of Alopecia Areata Childhood Alopecia Areata Study Using the 308-nm Excimer Laser Alefacept in Patients With Severe Scalp Alopecia Areata Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata

Brief Title

The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata

Official Title

The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata: A Single Group Case Series.

Brief Summary

      This study investigates the impact of mindfulness based cognitive therapy (MBCT) on social
      anxiety in adults with alopecia areata. A single-group case-series design will be adopted.
    

Detailed Description

      Alopecia areata (AA) is an immunological disorder which is characterised by round/oval
      patches of non-scarring hair loss. People living with AA are at higher risk of developing
      depression, anxiety and social phobia than the general population (Koo et al., 1994;
      Ruiz‐Doblado, Carrizosa, & García‐Hernández, 2003). Interventions that aim to reduce
      engagement in negative appearance related thoughts, and attentional bias towards negative
      self-referential information may be helpful for this population.

      Mindfulness-based cognitive therapy (MBCT) offers one potential method of reducing social
      anxiety in individuals with AA. MBC is a structured eight-week programme that has been
      recommended by the National Institute of Clinical Excellence as an effective intervention to
      reduce the risk of relapse in depression since 2009.

      The main aim of the current study is to investigate whether an MBCT course can reduce social
      anxiety in individuals with AA. A single-group case-series design will be adopted, whereby
      participants will act as their own control; data collected from participants during and after
      they have received the intervention will be compared to data collected before they have
      received the intervention. Semi-structured interviews will be carried out at the end of the
      study to investigate participants experiences of the intervention.

      The investigators predict that MBCT will reduce social anxiety in individuals with AA. More
      specifically, the hypothesis are:

      (i) participants will experience an increase in mindfulness during the intervention period,
      relative to the baseline phase and this will be maintained at follow-up

      (ii) increases in mindfulness will be associated with decreases in social anxiety, anxiety
      and depression, and increases in dermatology quality of life.
    


Study Type

Interventional


Primary Outcome

Change in social anxiety (idiosyncratic measure)

Secondary Outcome

 Social Anxiety

Condition

Alopecia Areata

Intervention

Mindfulness Based Cognitive Therapy

Study Arms / Comparison Groups

 Mindfulness-based cognitive therapy
Description:  There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Behavioral

Estimated Enrollment

6

Start Date

March 14, 2019

Completion Date

September 23, 2019

Primary Completion Date

August 20, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  AA is the main presenting physical health problem

          -  Participant self-identifies as experiencing social anxiety

          -  Sufficient English to participate in group sessions and discussion.

          -  Aged 16 and over

        Exclusion Criteria:

          -  Primary psychiatric diagnosis affecting skin (e.g., trichotillomania)

          -  Hair loss as a result of medical intervention or surgery (e.g., chemotherapy)

          -  The skin condition is secondary to other physical health problems (e.g., arthritis,
             cancer, chronic pain)

          -  Patient does not report any social distress as a result of their AA

          -  Currently undergoing other psychological therapy
      

Gender

All

Ages

16 Years - 99 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT03873155

Organization ID

230374


Responsible Party

Principal Investigator

Study Sponsor

University of Sheffield

Collaborators

 Alopecia UK

Study Sponsor

, , 


Verification Date

September 2019